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Abstract
Herein we report 2 cases of malignant lymphoma associated with Behçet’s disease. Case 1, a 53-year-
old  man,  was  diagnosed  as  Behçet’s  disease  at  the  age  of  26  years,  and  was  treated  with 
cyclophosphamide and prednisolone. At 45 years of age, bilateral enlarged lymph nodes were observed 
in the patient’s neck. Evaluation of a lymph node biopsy specimen showed Hodgkin’s disease and 
chemotherapy  was  administered.  Due  to  disease  recurrence  7  years  later,  chemotherapy  and 
radiotherapy were administered. Case 2, a 67-year-old male, was diagnosed as Behçet’s disease at age 
44 years and began colchicine treatment. At 60 years of age a mass in his left tonsillar fossa was noted. 
Evaluation  of  a  left  tonsil  biopsy  specimen  showed  malignant  lymphoma.  Radiotherapy  and 
chemotherapy were subsequently administered. At the time this report was written both patients were 
disease-free. Malignant lymphoma associated with Behçet’s disease is rare-only 17 cases have been 
published. In addition to the presented cases, the literature regarding malignant lymphoma associated 
with Behçet’s disease is reviewed. (Turk J Hematol 2011; 28: 327-34)
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Özet
Bu  yazıda,  Behçet  hastalığı  ile  birlikte  bulunan  iki  malign  lenfoma  olgusu  sunulmuştur.  Elli  üç 
yaşındaki ilk olguya 26 yaşında Behçet hastalığı tanısı konmuş ve üç yıl siklofosfamid ve prednizolon 
ile tedavi edilmiştir. Kırk beş yaşında boyunda lenf nodları tespit edilmiştir. Lenf nodu biyopsisi sonucu 
Hodgkin hastalığı tanısı konmuş ve kemoterapi uygulanmıştır. Yedi yıl sonra hastalık relapsı nedeniyle 
kemoterapi  ve  radyoterapi  uygulanmıştır.  Altmış  yedi  yaşındaki  ikinci  olguya  23  yıl  önce  Behçet 
hastalığı tanısı konmuş ve kolsişin başlanmıştır. Altmış yaşında sol tonsiller fossada kitle saptanmıştır. 
Sol  tonsilden  alınan  biyopsi  sonucu  malign  lenfoma  tanısı  konmuş,  radyoterapi  ve  kemoterapi 
uygulanmıştır. Her iki hasta da lenfoma açısından hastalıksız izlenmektedir. Aynı hastada bu iki farklı 
TJH-ARALIK-2011-4-crossref.indd   79 02.12.2011   10:14hastalığın  birlikteliği  nadirdir.  Literatürde  bu  birliktelik  sedece  17  olguda  bildirilmiştir.  Sunulan 
olgular  bazında,  Behçet  hastalığı  ve  malign  lenfomanın  olası  ilişkisi  konusunda  literatür  gözden 
geçirilmiştir. (Turk J Hematol 2011; 28: 327-34)
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Introduction
Behçet’s disease (BD) was first described by Dr. 
Hulusi Behçet in 1937 as a triad of recurrent aph-
thous ulceration of oral and genital mucosa, and 
relapsing  hypopyon  uveitis  [1].  It  is  now  recog-
nized  as  a  multisystem  inflammatory  disorder 
characterized by vasculitis [2]. Although the exact 
etiology of BD is unknown, some genetic, immu-
nologic, and infectious factors are suspected in the 
pathogenesis [3]. The treatment of BD is empirical 
and usually includes systemic corticosteroids, and 
immunosuppressive  and/or  cytotoxic  agents  [4]. 
The literature contains few reports of the coexis-
tence of malignant disease in BD patients-to date 
only  96  cases  (excluding  myelodysplastic  syn-
dromes) have been reported, of which 17 are lym-
phoid malignancy [5-19]. Malignant transformation 
in BD might be due to the autoimmune nature of 
BD, triggering infectious agents, or the drugs used 
for the management of BD. 
Case Reports
Case 1
A  53-year-old  male  patient  was  diagnosed  as 
uveitis in 1979 (at the age of 26 years), due to hazy 
vision and impaired visual acuity; periorbital steroid 
injections  were  subsequently  administered.  Six 
months following the diagnosis of uveitis, recurrent 
oral and genital aphthous ulcers, and papulopustu-
lar skin lesions on the nape of the neck, back, and 
chest  were  observed;  therefore,  the  patient  was 
subsequently  diagnosed  as  BD  and  treated  with 
cyclophosphamide and prednisolone for 3 years. 
In February 1998, bilateral enlargement of multi-
ple lymph nodes in the neck was noted. Evaluation 
of the cervical lymph node biopsy specimen showed 
nodular  lymphocyte-predominant  Hodgkin’s  dis-
ease (HD) (Figure 1). Computed tomography (CT) 
of the thorax and abdomen were normal, and bone 
marrow aspiration was negative. Based on the diag-
nosis of stage II-B HD, vincristine, epirubicine, eto-
poside, and prednisolone (VEEP) combination che-
motherapy was administered by the medical oncol-
ogy department. 
During  the  course  of  chemotherapy  both  the 
number  and  frequency  of  oral  lesions  increased. 
Following  8  courses  of  chemotherapy  the  patient 
achieved complete remission and was followed-up. 
In August 2005 the patient was restaged due to the 
observation of enlarged lymph nodes in the right 
axilla. Thoracic CT showed multiple enlarged lymph 
nodes  in  the  right  axilla  and  left  supraclavicular 
fossa. Abdominopelvic CT was considered normal. 
Four courses of doxorubicin, bleomycin, vinblastin, 
and dacarbazine (ABVD) combination chemothera-
py were administered, and complete remission was 
achieved. 
The patient presented to our department for the 
first  time  in  December  2005  for  consolidative 
radiotherapy (RT). The lower neck, bilateral infra-
supraclavicular  fossa,  bilateral  axilla,  and  upper 
mediastinum were irradiated with cobalt 60 pho-
tons using a Theratron 780 C cobalt linear accel-
erator (Best Theratronics LTD., Ontario, Canada). A 
total dose of 30.6 Gy was delivered in fractions of 
1.8 Gy/d. During and after the RT no early toxicity 
associated with RT was observed, except for grade 
1 hyperemia of the skin and dysphagia. Interestingly, 
the patient complained of a burning sensation at 
the irradiated region a few weeks after the com-
pletion of RT, but physical examination was unre-
markable. One week later the burning sensation 
spontaneously abated. At the time this report was 
written the patient had been followed-up disease-
free for 4 years post RT and late toxicity associated 
with RT was not observed. The patient has com-
plete vision loss in the right eye and stable partial 
vision loss in the left eye associated with BD. Oral 
and genital ulcers erupt every 2-3 weeks, and dis-
appear 2-3 d later.
TJH-ARALIK-2011-4-crossref.indd   80 02.12.2011   10:14Case 2
A 67-year-old male patient was first diagnosed 
as BD at age 44 years due to uveitis in the right eye, 
oral  aphthous  ulcers,  scrotal  ulcers,  and  pseudo 
follicular skin lesions that erupted once a week. As 
such, the patient was treated with colchicine. In 
February 2002 the patient complained of swelling 
on the left side of his neck and difficulty swallow-
ing.  CT  of  the  head  and  neck  showed  a  mass 
lesion  in  the  left  tonsillar  fossa  and  multiple 
enlarged lymph nodes in the left cervical region. A 
biopsy specimen obtained from the left tonsil was 
evaluated as high-grade malignant lymphoma, dif-
fuse large B-cell-type (Figure 2). CT of the thorax 
and abdomen, and bone marrow aspiration were 
negative. 
The patient presented to our department for the 
first time in September 2002 for RT. The Waldeyer 
field and bilateral neck were irradiated with cobalt 
60 photons using a Theratron 780 C cobalt linear 
accelerator  (Best  Theratronics  LTD.,  Ontario, 
Canada). A total dose of 45 Gy was delivered in frac-
tions  of  1.8  Gy  d–1.  During  and  after  RT  no  early 
toxicity associated with RT was observed, except 
for grade 1 hyperemia of the skin, mucositis, and 
dysphagia.  Following  RT,  4  courses  of  cyclophos-
phamide, doxorubicin, vincristine, and prednisone 
(CHOP) combination chemotherapy were adminis-
tered. At the time this report was written the patient 
had been followed-up disease-free for 7 years post 
RT  and  no  late  toxicity  associated  with  RT  was 
observed, except for grade 1 xerostomia. The patient 
has not used colchicine since 2003 and has com-
plete vision loss in the right eye associated with BD. 
Oral and genital ulcers erupt every 2-3 d, and disap-
pear 2-3 d later.
Discussion
BD is a chronic, relapsing multisystem connec-
tive tissue disorder characterized by vasculitis in the 
mucocutaneous, ocular, gastrointestinal, respirato-
ry, neurologic, urogenital, articular, and cardiovas-
cular systems [20]. Other connective tissue disor-
ders, including Sjögren’s syndrome, dermatomyosi-
tis, rheumatoid arthritis, and systemic lupus erythe-
matosus, are known to be associated with malig-
nancy [21-23], and this association has been further 
supported  by  recent  epidemiologic  research. 
Nevertheless, the worldwide prevalence of BD and 
the  possible  association  between  malignant  dis-
eases  and  BD  remain  unclear.  Only  96  cases  of 
malignancy associated with BD have been report-
ed; 63 cases had solid organ tumors, 16 cases had 
hematological malignancies, and 17 cases had lym-
phoid malignancies [5-19] (Table 1). 
BD is one of the most common forms of vasculi-
tis  in  the  Turkish  population;  the  reported  preva-
lence  varies  from  80/100,000  to  370/100,000  [4]. 
Cengiz et al. [13] reported 400 BD patients during a 
13-year period; malignancy developed in 13 (3.25%) 
patients, 2 (0.5%) of which had malignant lympho-
ma.  A  study  that  included  387  BD  patients  from 
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Figure 2. Microscopic Appearance of Tonsil Infiltrated By Malignant 
Lymphoma (H&E, 200×)
Figure 1. Microscopic Appearance of Mononuclear Hodgkin’s Cells 
(Arrows) Infiltrating the Paracortical Lymphoid Tissue Between the 
Follicular Region (H&E, 200×)
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malignancy during 20 years of follow-up, 1 (0.51%) 
of which was diagnosed as malignant lymphoma 
[15].  Between  1992  and  2007,  440  patients  with 
malignant lymphoma presented to our department, 
of which only 2 (0.45%) were previously diagnosed 
with BD.
Case 1 is only the third case of HD associated 
with  BD  to  be  reported.  The  previously  reported 
cases of HD associated with BD were mixed cellu-
larity type (n=1) and nodular sclerosing type (n=1) 
[9,13], whereas the histopathological subtype was 
nodular  lymphocyte  predominant  in  case  1.  The 
previous  mixed  cellularity-type  case  was  treated 
Meydan et al.
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Table 1. Reported Cases of Malignant Lymphoma Associated with Behçet’s Disease
No.  Author  Age  Therapy  Period  Histology  Sites of  EBV   Radiotherapy 
  (year)  (years)/sex  for BD  between BD    involvement 
        and lymphoma
1  Kaneko et al.   32/F  PSL,  -    Nasal malignant    RT 
  (1974) [5]    indomethacin       lymphoma   
2  Houston et al.   59/F    5 years  Diffuse      RT 
  (1978) [6]        lymphocytic 
          lymphoma
3  Moulongeut-Michau  31/M  colchicine  13 years  Angiocentric  Skin 
  et al. (1990) [7]        lymphoma 
          (helper T-cell)
4  Harada et al.   43/F  colchicine  9 months  Diffuse large  Cerebellum    RT 
  (1992) [8]        B cell 
  positive 
5   Kawamoto et al.   43/M  PSL  1 years  HD, mixed  Liver, spleen,     
  (1992) [9]        cellularity   neck, etc.
6  Abe et al.   43/F  NSAID  15 years  Small lymphocytic  Gastric 
  (1993) [10]        B Cell  lymphoma
7  Yamamoto el al.   45/M  colchicine,   19 years  Diffuse large  Neck     
  (1997) [11]    betamethasone    cell  lymph nodes
8  Houman et al.   37/F  colchicine,   2.5 years  Large B cell  Small intestine 
  (2001) [12]    CPA, cyclosporin
9  Cengiz et al.   47/M  CPA, indomethacin  7 years  HD, nodular      RT, 40 Gy 
  (2001) [13]        sclerosing
10  Cengiz et al.   42/F  colchicine,   8 years  Diffuse  Lymph nodes     
  (2001) [13]    indomethacin    mixed cell
11  Katsura et al.   49/M  PSL, colchicine,   1 years  Cytotoxic T cell  perirenal,   positive   
  (2003) [14]    cyclosporin      orbital, esophagus
12 Kural-Seyahi et al.   49/M  Chlorambucil/   20 years  High-grade       
  (2003) [15]    azathioprine or CPA    lymphoma
13  Ono et al.   75/F  PSL, colchicine  17 years  Diffuse B cell  Cerebrum,  negative  RT, 50 Gy 
  (2005) [16]          ileum 
14  Chelly et al.   40/M  PSL, azathioprine  2 years  Gamma delta  cutaneous     
  (2008) [17]        T cell
15  Souabni et al.   32/M  colchicine, indomethacin,  14 years  Large B cell  Right tonsil  positive  RT, 45 Gy 
  (2008) [18]    PSL, dapsone
16  Ahn et al.   39/F  PSL, colchicine,   19 months  Gastric MALToma  Stomach     
  (2010) [19]    cyclosporin, azathiopririne
17  Ahn et al.   18/F  PSL, colchicine,   46 months  Extranodal     
  (2010) [19]    cyclosporin, azathiopririne    NK-T cell lymphoma       
18  Present case  53/M  PSL, CPA  19 years  HD, nodular  Neck, right axilla  negative  RT, 30.6 Gy 
          lymphocyte- 
          predominance
19  Present case  64/M  colchicine  20 years  Diffuse large B cell  Left tonsil  negative  RT, 45 Gy
BD: Behçet’s disease; HD: Hodgkin’s disease; M: male; F: female; PSL: prednisolone; NSAID: non-steroidal anti-inflammatory drug; CPA: cyclophosphamide
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sclerosing-type  case  was  treated  with  cyclophos-
phamide and indometacin for BD, whereas case 1 
was treated with prednisolone and cyclophospha-
mide. 
Previous reports of malignant lymphoma associ-
ated with BD are mostly extranodal, whereas only 2 
cases had nodal involvement [11,13]. Case 2 is con-
sidered by us to be the 16th reported case of malig-
nant lymphoma associated with BD and only the 
2nd case of tonsil involvement; the treatment for BD 
in this patient was colchicine. 
The pathogenesis of BD remains to be discerned, 
although infectious, immunologic, and genetic fac-
tors have been implicated [20]. The pathophysiolo-
gy of BD is considered to involve excess function of 
neutrophils,  vascular  damage  associated  with 
thrombus  formation,  and  lymphocyte  dysfunction 
[24].  The  major  immunologic  features  of  BD  are 
increased T-cell and B-cell response to heat-shock 
proteins,  increased  neutrophil  activity,  and  altera-
tion  in  cytokine  levels  [4].  Additionally,  helper 
T-cells  and  macrophages  are  known  to  exhibit 
immunological dysfunction, as well as neutrophils 
[10]. Development of malignancy in autoimmune 
diseases  and  vasculitides  could  be  related  to 
immune  regulation  abnormality,  T-cell  deficiency, 
or over proliferation of B-cells, which may trigger 
the malignant transformation of cells [20]. Moreover, 
the above-mentioned immunological features of BD 
might be associated with the development of malig-
nancy. 
All  BD  cases  are  devoid  of  any  documented 
cause of lymphoid malignancy, other than the pos-
sibility of drug-induced etiology, the immunological 
features of BD, or immune system stimulation via 
an infectious agent. Several genetic diseases, and 
environmental  and  infectious  agents  have  been 
associated  with  the  development  of  lymphoma 
[25]. The frequency of non-Hodgkin’s lymphoma is 
much  higher  in  immunocompromised  patients 
[26]. Patients with autoimmune and chronic inflam-
matory  disorders  have  an  increased  risk  for  the 
development of non-Hodgkin’s lymphoma [27]. In 
non-Hodgkin’s lymphoma, as in BD, disturbances 
in  T-cell  compartment  and  T-cell  dysfunction-
including low autologous mixed lymphocyte reac-
tion-have been reported [10]; therefore, between 
BD and development of lymphoma may be a rela-
tionship. Cohort studies and meta-analyses show 
that non-Hodgkin’s lymphoma is more common in 
patients  with  autoimmune  diseases,  especially 
those with Sjögren’s syndrome, systemic lupus ery-
thematosus, and rheumatoid arthritis, than in the 
general  population;  however,  such  data  are  not 
available  for  BD  [27,28].  Immunosuppressive 
agents are thought to be involved in the pathophys-
iology of malignancy [29]. Numerous studies have 
implicated the use of immunosuppressive agents, 
such as chlorambucil, cyclophosphamide, and col-
chicine, in the etiology of lymphoma transforma-
tion in BD. Previous research reports that there is a 
significantly elevated risk of lymphoma in associa-
tion  with  use  of  non-steroidal  anti-inflammatory 
drugs, corticosteroids, and other immunosuppres-
sants [30]. 
Steroids  inhibit  the  activation  and  growth  of 
T-cells, and reduce the number of peripheral lym-
phocytes. Steroids also inhibit B-cell maturation at 
an  early  stage  by  inhibiting  interaction  between 
monocytes and T-cells [16]. The exact mechanism 
of the steroid function is not known, but all steroid 
characteristics might be related to late onset malig-
nant  lymphoma  [16].  Colchicine  is  usually  pre-
scribed  for  mucocutaneous  disease,  arthritis,  and 
genital ulcers [4]; this drug suppresses phagocytosis 
and  emigration  of  white  blood  cells,  and  inhibits 
chemotactic responses of neutrophils to chemotac-
tic cytokines [16]. Sauabni et al. [18] also attributed 
lymphoma transformation to the mutagenic effect 
of colchicine in animals. Long-term administration 
of colchicine in patients with BD may induce malig-
nant lymphoma. Cyclophosphamide is usually used 
to treat BD patients that are unresponsive to other 
therapies [4]. Long-term treatment of autoimmune 
disease patients with alkylating agents (e.g. cyclo-
phosphamide) might result in secondary neoplastic 
disease;  therapy-related  myelodysplasia/acute 
myeloid leukemias are a well-known consequence, 
yet therapy-related lymphomas are less well-known 
in  patients  with  autoimmune  disease  [31].  The 
period between the onset of BD and malignant lym-
phoma varies from 9 months to 20 years, and immu-
nosuppressive agents and steroids have not been 
administered  in  all  reported  cases  (Table  1). 
Moreover, following transplantation and treatment 
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most  malignancies  arise  within  6  months  [16]. 
Thus, it is difficult to discern if the effects of immu-
nosuppressive agents used in the treatment or the 
underlying immune mechanism are responsible for 
the  association  between  BD  and  malignant  lym-
phoma.
Immune  system  stimulation  via  an  infectious 
agent  has  been  suggested  to  play  a  role  in  the 
pathogenesis of BD [4]. Infectious agents are also 
implicated  in  the  pathogenesis  of  Hodgkin’s  and 
non-Hodgkin’s  lymphoma  [25,32].  Epstein-Barr 
virus (EBV) infection is associated with neoplastic 
proliferation  in  immunosuppressed  transplant 
recipients [33]. Of the 15 cases of malignant lym-
phoma associated with BD previously reported, 3 of 
the 4 that were tested for EBV infection were posi-
tive [8,14,18]. In the presented cases, immunohisto-
chemical staining on paraffin tissues did not indi-
cate  the  presence  of  EBV  (anti-EBV/LMP  Ab-1, 
ms-1458, Thermo Fisher Scientific, Pittsburgh, PA). 
Moreover, EBV infection is associated, in particular, 
with mixed cellularity-type HD [32]; Only 1 previ-
ously reported case of HD associated with BD was 
mixed cellularity-type. 
Another point is use of radiation for the treatment 
of malignancy in BD. Numerous studies report that 
CVD predisposes patients to increased toxicity from 
therapeutic irradiation [34-38]; however, consider-
ing the effects of RT in patients with BD, the litera-
ture is lacking sufficient data, as there are only a few 
reports on the use of radiation in BD patients. In a 
part  of  these  reports,  the  authors  had  not  been 
referred  to  radiation  toxicity  [16,18,20,39].  Low-
dose  total  lymphoid  irradiation  treatment  in  5 
patients with intractable BD was reported; no mor-
bidity  related  to  irradiation  occurred,  presumably 
because of the relatively low doses used [13]. 
Strohal et al. [40] reported a BD patient treated 
with a combination of chemotherapy and 40-Gy of 
radiation  administered  to  the  heart,  and  cervical 
and  mediastinal  lymph  nodes  for  treatment  of 
comorbid  multicentric  Castleman’s  disease.  The 
researcher  reported  that  the  treatment  was  well-
tolerated,  but  did  not  discuss  radiation  toxicity. 
Cengiz et al. [13] treated 6 BD patients with RT due 
to malignant disease, and reported that there wasn’t 
an  increase  in  the  incidence  or  severity  of  acute 
radiation morbidity. In all, 3 of the 6 patients (1 with 
HD, 1 with a malignant mesenchymal tumor, and 1 
with ureteral fibrosis) developed late radiation reac-
tions,  including  brachial  plexopathy  and  dermal 
necrosis.  Recently,  Chargari  et  al.  [41]  reported 
adjuvant whole-breast RT for left breast ductal car-
cinoma in situ in a patient with quiescent BD. At a 
dose of 44 Gy acute grade 3 radioepithelitis occurred, 
which necessitated cessation of RT. The research-
ers  reported  that  the  radiation-induced  vascular 
lesions  were  similar  to  the  vasculitis  observed  in 
BD. In the presented cases we did not observe an 
increase in the severity of acute or late reactions 
related to irradiation, perhaps because of the rela-
tively low total doses administered. 
Malignant lymphoma associated with BD is very 
rare. For the development of lymphoid malignancy 
in BD or, to establish an association between these 
2  diseases,  the  roles  of  immunologic  factors  or, 
drugs used for the treatment or, infectious agent are 
not clear yet. Due to the above-mentioned distur-
bances or, indeterminate other factors, there may 
be an association between BD and malignant lym-
phoma, but this may also be a hazardous coinci-
dence. Based on all available data, it is difficult to 
conclude  that  RT  increases  the  incidence  and 
severity of radiation reactions in BD patients; how-
ever, doses exceeding 40 Gy, especially in patients 
with active BD, should be administered with cau-
tion.
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